:ID,name,:LABEL,understanding_criteria,schema_version,description,author,creation_date,last_updated,total_concepts:int,level,prerequisites
GP_NEPH_RTA,Renal tubular acidosis in children and relevant fundamental renal physiology,Curriculum,,1.0.0,Renal tubular acidosis in children and relevant fundamental renal physiology,,2025-12-14,2025-12-14,8,,
GPNEPHRTA_001,Fundamental Distinction Between Uraemic Acidosis and Renal Tubular Acidosis,Concept,"Recognise that uraemic acidosis results from loss of functional nephrons affecting both glomeruli and tubules, typically with GFR <20-30 mL/min, though mixed patterns can occur;Identify that uraemic acidosis causes high anion gap metabolic acidosis (HAGMA) due to accumulation of acidic anions such as phosphate and sulfate;Understand that renal tubular acidosis (RTA) involves defects isolated to the renal tubules with GFR that may be normal or only minimally affected;Recognise that RTA results in hyperchloremic normal anion gap metabolic acidosis (NAGMA) due to impaired ability to acidify urine and excrete acid;Differentiate that uraemic acidosis patients manifest as renal failure with chronic complications like bone demineralisation, while RTA may be detected incidentally or present with failure to thrive, dehydration, or metabolic decompensation",1.0.0,"Understanding fundamental distinction between uraemic acidosis and renal tubular acidosis: Recognise that uraemic acidosis results from loss of functional nephrons affecting both glomeruli and tubules, typically with GFR <20-30 mL/min, though mixed patterns can occur",,2025-12-14,2025-12-14,,Foundational,
GPNEPHRTA_002,GP Approach to Child with Normal Anion Gap Metabolic Acidosis (NAGMA),Concept,"Confirm metabolic acidosis using venous blood gas showing low pH and low HCO3-, and assess respiratory compensation (expected pCO2 = 1.5 × HCO3 + 8 ± 2);Calculate anion gap using [Na+] - ([Cl-] + [HCO3-]) with normal range 8-12 mmol/L to differentiate NAGMA from HAGMA;Identify common non-RTA causes of NAGMA in children: diarrhoea, ileostomy losses, ureterosigmoidostomy, excessive normal saline administration;Order initial investigations: serum electrolytes including potassium, creatinine/eGFR, glucose, venous blood gas, and spot urine for pH, sodium, potassium, chloride, and urinalysis with culture;Assess clinical severity: dehydration status, growth parameters, conscious state, presence of vomiting or polyuria;Identify red flags requiring emergency department referral: severe acidaemia (HCO3 <10 mmol/L or pH <7.20), significant dehydration or shock, altered consciousness, cardiac arrhythmia risk with severe hypokalaemia (<2.5 mmol/L) or hyperkalaemia (>6.5 mmol/L);Calculate urine anion gap (UAG = urine [Na+] + [K+] - [Cl-]) to differentiate GI bicarbonate loss (negative UAG due to high NH4+ excretion) from RTA (positive or less negative UAG due to impaired NH4+ excretion);Initiate paediatric nephrology referral when RTA is suspected based on NAGMA with positive UAG and no clear GI cause",1.0.0,"Understanding gp approach to child with normal anion gap metabolic acidosis (nagma): Confirm metabolic acidosis using venous blood gas showing low pH and low HCO3-, and assess respiratory compensation (expected pCO2 = 1.5 × HCO3 + 8 ± 2)",,2025-12-14,2025-12-14,,Foundational,
GPNEPHRTA_003,Clinical Presentation and Recognition of RTA in Children,Concept,"Recognise that infants and young children with RTA commonly present with failure to thrive, poor weight gain, and growth faltering;Identify that vomiting, polyuria, polydipsia, and dehydration are common presenting features in children with RTA;Understand that children may present with muscle weakness, fatigue, or hypotonia due to hypokalaemia (particularly in Type 1 and Type 2 RTA);Recognise that rickets or bone pain may occur due to chronic acidosis affecting bone mineralisation, with features including bowing of legs, widened wrists/ankles, and elevated alkaline phosphatase;Identify that some children are diagnosed incidentally through routine blood tests showing metabolic acidosis with normal anion gap;Understand that recurrent urinary tract infections, haematuria, or abdominal pain may be presenting features in children with nephrocalcinosis or nephrolithiasis secondary to distal RTA;Recognise that developmental delay or altered mental state can occur in severe or prolonged untreated cases",1.0.0,"Understanding clinical presentation and recognition of rta in children: Recognise that infants and young children with RTA commonly present with failure to thrive, poor weight gain, and growth faltering",,2025-12-14,2025-12-14,,Intermediate,
GPNEPHRTA_004,"Type 1 (Distal) RTA: Pathophysiology, Clinical Features, and Aetiology",Concept,"Identify that distal RTA is characterised by reduced secretion of H+ in the distal tubule and collecting duct, resulting in inability to maximally acidify urine;Recognise that urine pH remains inappropriately >5.5 during systemic acidosis (HCO3 <15 mmol/L) as the hallmark diagnostic feature;Explain that failure to excrete acid load leads to severe metabolic acidosis with plasma HCO3 typically <15 mmol/L, with bone and extracellular buffers compensating;Understand that secondary hyperaldosteronism results in increased urinary K+ loss, leading to hypokalaemia or low-normal potassium;Identify the triad of hyperchloremic acidosis, inappropriately alkaline urine during acidosis, and predisposition to renal stone formation as characteristic of distal RTA;Explain that hypercalciuria, hypocitraturia, and alkaline urine predispose children to early-onset nephrocalcinosis and calcium phosphate nephrolithiasis;Recognise hereditary causes as most common in children, including mutations in ATP6V1B1 or ATP6V0A4 (often associated with sensorineural hearing loss) and SLC4A1;Identify acquired causes including autoimmune conditions (Sjögren syndrome, SLE, autoimmune thyroiditis), nephrocalcinosis (primary hyperparathyroidism, vitamin D intoxication), and nephrotoxins (amphotericin B, toluene inhalation)",1.0.0,"Understanding type 1 (distal) rta: pathophysiology, clinical features, and aetiology: Identify that distal RTA is characterised by reduced secretion of H+ in the distal tubule and collecting duct, resulting in inability to maximally acidify urine",,2025-12-14,2025-12-14,,Intermediate,
GPNEPHRTA_005,"Type 2 (Proximal) RTA: Pathophysiology, Clinical Features, and Aetiology",Concept,"Identify that proximal RTA is caused by impaired reabsorption of bicarbonate in the proximal tubule, with intact distal acidification mechanisms;Understand that when plasma HCO3 is above the reduced reabsorption threshold, filtered bicarbonate is lost in urine and urine pH may be >5.5; once plasma HCO3 falls below the threshold, the urine can acidify to <5.5;Recognise that metabolic acidosis is usually less severe than distal RTA with plasma HCO3 typically >15 mmol/L;Explain that increased distal tubular Na+ delivery causes secondary hyperaldosteronism, leading to urinary K+ wasting and hypokalaemia;Identify that hyperchloraemia occurs as Cl- replaces lost HCO3- in the circulation to maintain electroneutrality;Recognise hereditary causes including mutations in SLC4A4 (NBCe1 cotransporter) and carbonic anhydrase II deficiency;Identify that Type 2 RTA may be part of Fanconi syndrome with generalised proximal tubular dysfunction causing impaired reabsorption of glucose, phosphate, amino acids, and bicarbonate;Recognise acquired causes including cystinosis, vitamin D deficiency, lead nephropathy, amyloidosis, and medullary cystic disease",1.0.0,"Understanding type 2 (proximal) rta: pathophysiology, clinical features, and aetiology: Identify that proximal RTA is caused by impaired reabsorption of bicarbonate in the proximal tubule, with intact distal acidification mechanisms",,2025-12-14,2025-12-14,,Intermediate,
GPNEPHRTA_006,Type 4 RTA and Type 3 RTA: Pathophysiology and Clinical Features,Concept,"Identify that Type 4 RTA is characterised by hypoaldosteronism or aldosterone resistance, resulting in impaired distal tubular cation exchange;Recognise that Type 4 RTA is always associated with hyperkalaemia, unlike Type 1 and Type 2 RTA which typically cause hypokalaemia;Understand that reduced aldosterone activity impairs both H+ and K+ secretion in the distal tubule and also reduces proximal tubular ammoniagenesis, decreasing urine buffering capacity;Identify that patients with Type 4 RTA can acidify urine to pH <5.5 because the H+ pump itself is not defective, distinguishing it from Type 1 RTA;Recognise that Type 4 RTA causes mild metabolic acidosis with plasma HCO3 usually >15 mmol/L and may occur with mild-to-moderate CKD or near-normal GFR;Identify causes of Type 4 RTA including aldosterone deficiency (Addison disease, post-bilateral adrenalectomy, hyporeninemic hypoaldosteronism in diabetic nephropathy) and aldosterone resistance from drugs (NSAIDs, ACE inhibitors, ARBs, spironolactone, eplerenone, trimethoprim, pentamidine);Recognise Type 3 RTA as a rare mixed proximal and distal RTA due to carbonic anhydrase II deficiency, often presenting in children with osteopetrosis, cerebral calcifications, and developmental delay",1.0.0,"Understanding type 4 rta and type 3 rta: pathophysiology and clinical features: Identify that Type 4 RTA is characterised by hypoaldosteronism or aldosterone resistance, resulting in impaired distal tubular cation exchange",,2025-12-14,2025-12-14,,Advanced,
GPNEPHRTA_007,Diagnostic Differentiation of RTA Types Using Practical Laboratory Parameters,Concept,"Identify that all types of RTA present with hyperchloremic normal anion gap metabolic acidosis (NAGMA) with anion gap 8-12 mmol/L;Use urine pH during systemic acidosis to differentiate: Type 1 (distal) inappropriately >5.5, Type 2 (proximal) can be <5.5 once plasma HCO3 falls below reabsorption threshold, Type 4 can be <5.5;Recognise limitations of urine pH: affected by urinary tract infection with urease-producing organisms, dietary factors, and sample handling delay; fresh sample required;Use plasma HCO3 levels to differentiate severity: Type 1 typically <15 mmol/L (severe), Type 2 and Type 4 usually >15 mmol/L (mild-moderate);Use plasma potassium to differentiate: Type 1 and Type 2 show hypokalaemia or low-normal K+, Type 4 shows hyperkalaemia;Recognise that nephrocalcinosis and renal stones occur in Type 1 (distal) RTA but not typically in Type 2 or Type 4;Calculate urine anion gap (UAG = urine [Na+] + [K+] - [Cl-]) as a practical proxy for urinary NH4+ excretion: positive UAG suggests RTA (impaired NH4+ excretion), negative UAG suggests GI bicarbonate loss (intact renal NH4+ excretion);Understand that provocative tests (NH4Cl loading, bicarbonate loading) are specialist investigations not routinely performed in general practice; sufficient evidence for referral includes NAGMA with positive UAG and clinical features",1.0.0,Understanding diagnostic differentiation of rta types using practical laboratory parameters: Identify that all types of RTA present with hyperchloremic normal anion gap metabolic acidosis (NAGMA) with anion gap 8-12 mmol/L,,2025-12-14,2025-12-14,,Advanced,
GPNEPHRTA_008,"Treatment Principles, Monitoring, and Shared Care for RTA in Children",Concept,"Recognise that treatment goals include correction of acidosis to promote normal growth, prevention of bone disease, prevention of nephrocalcinosis (Type 1), and correction of electrolyte abnormalities;Identify that Type 1 (distal) RTA treatment includes oral sodium bicarbonate or sodium/potassium citrate solutions to correct acidosis, sodium deficit, and hypokalaemia; citrate also binds urinary calcium to help prevent renal stones;Understand that Type 2 (proximal) RTA may not always require alkali therapy if acidosis is mild; when required, large doses of bicarbonate are needed due to ongoing urinary losses; thiazide diuretics may increase proximal HCO3 reabsorption in some patients;Recognise that Type 4 RTA treatment focuses on addressing hyperkalaemia and treating the underlying cause; potassium-containing alkali preparations are contraindicated;Identify safety considerations: avoid excessive sodium load (risk of hypertension and volume overload), monitor potassium carefully when using potassium citrate, review medications that may contribute (ACE inhibitors, ARBs, NSAIDs, trimethoprim);Understand that specialist paediatric nephrology leads diagnosis confirmation, treatment initiation, and dose titration; most children require ongoing specialist care;Recognise the GP role in shared care: monitor adherence to medications, track growth parameters (height, weight, growth velocity), manage intercurrent illnesses (vomiting/poor intake worsens acidosis and may require temporary dose adjustment or hospital review), and coordinate with specialist team;Identify monitoring requirements: regular serum electrolytes (Na+, K+, Cl-, HCO3-), venous blood gas, renal function (creatinine/eGFR), and for Type 1 RTA periodic renal ultrasound to monitor for nephrocalcinosis; bone health assessment (ALP, phosphate, vitamin D, PTH) if rickets suspected;Understand that children with inherited RTA and sensorineural hearing loss (associated with some distal RTA mutations) require audiology follow-up",1.0.0,"Understanding treatment principles, monitoring, and shared care for rta in children: Recognise that treatment goals include correction of acidosis to promote normal growth, prevention of bone disease, prevention of nephrocalcinosis (Type 1), and correction of electrolyte abnormalities",,2025-12-14,2025-12-14,,Advanced,
